fate-nk100
Cell therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 27, 2017 (NCT03081780)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Melanoma · Phase 1
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Stomach Neoplasms · Phase 1
Mechanism of action
- Natural killer cellSupplementation
Natural killer cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- fate-nk100
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03319459 | Phase 1 | Jan 18, 2018 | Fate Therapeutics |
| NCT03213964 | Phase 1 | Oct 19, 2017 | University of Minnesota |
| NCT03081780 | Phase 1 | Apr 27, 2017 | University of Minnesota |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Minnesota | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Fate Therapeutics | For profit | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1